Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of OT-101 (atropine sulfate 0.01%) for pediatric myopia progression
CTR20213283Phase 3Active
- Sponsor
- Ocumension Biotech
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atropine in myopia, sponsored by Ocumension Biotech. Started Mar 2022; status: active.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on CTR20213283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213283.